NSC 638850
Staurosporine, 7b-Hydroxy, Streptomyces sp. Tan solid. PROTECT FROM LIGHT. PACKAGED UNDER INERT GAS. A cell-permeable Staurosporine (Cat. No. 569397) derived anticancer agent that reversibly and ATP-competitively inhibits several protein kinases (IC50 = 29 nM, 34 nM, 30 nM, 590 nM and 530 nM for PKCa, PKCb, PKCg, PKCd and PKCe; IC50 = 7 nM, 27 nM, 50 nM, 50 nM, 150 nM and 1.04 µM for Chk1, Cdc25C-associated protein kinase 1, Cdk1, PAK4, Cdk5/p25 and Chk2; IC50 = 33 nM, 50 nM, 95 nM, 500 nM, 500 nM and 1.0 µM for PDK1, lck, MAPKAP kinase-2, Akt, GSK-3b and PKA, respectively). At higher concentrations (> 15 µM), affects the activities of Src, PIM-1, CKII, DNA-PK, ErK1, ILK-1 and MAPKK1). Reported to suppress thymidylate synthase expression, induce apoptosis with caspase activation, and sensitize tumor cells to a range of DNA-damaging agents. Purity: ≥98% by HPLC. CAS 112953-11-4. Ref.: Reinhardt, H.C., et al. 2007. Cancer Cell 11, 175. Jiang, X., et al. 2004. Mol. Cancer Ther. 3, 1221. Sato, S., et al. 2002. Oncogene 21, 1727. Patel, V., et al. 2002. Clin. Cancer Res. 8, 3549. Leclerc, S., et al. 2001. J. Biol. Chem. 276, 251. Busby, E.C., et al. 2000. Cancer Res. 60, 2108. Hsueh, C.T., et al. 1998. Clin. Cancer Res. 4, 2201. Akiyama, T., et al. 1997. Cancer Res. 57, 1495. Seynaeve, C.M., et al. 1994. Mol. Pharmacol. 45, 1207. Takahashi, I., et al. 1987, J. Antibiot. 40, 1782. |
